Posted by Michael Wonder on 02 Aug 2018
Aimovig (erenumab), a novel treatment developed specifically for migraine prevention receives Health Canada approval
2 August 2018 - Aimovig consistently shown to reduce monthly migraine days, with many patients achieving a 50% reduction or more.
Novartis Pharmaceuticals Canada is pleased to announce that Health Canada has approved Aimovig (erenumab) for the prevention of migraine in adults who have at least four migraine days per monthi. Migraine is a debilitating neurological diseaseiii that affects almost three million Canadians. It is associated with a substantial social and economic impact and considered the third most prevalent illness in the world.
The Health Canada approval of Aimovig is based on the results of two pivotal studies across the spectrum of chronic and episodic migraine.
